BPC-157 is systemic. Animal studies consistently show that it produces healing effects regardless of whether it’s injected near an injury, injected far from it, or taken orally. The peptide enters the bloodstream, crosses the blood-brain barrier, and influences multiple organ systems even when administered at a site distant from the target tissue.
What “Systemic” Means for BPC-157
A systemic compound is one that travels through your bloodstream and affects your whole body, not just the spot where it was applied. BPC-157 fits this definition. Research has demonstrated positive healing outcomes through oral administration (dissolved in drinking water), topical application (via cream), and injection into the abdominal cavity. One 90-day study used all three delivery methods and found therapeutic benefit across each one, suggesting the peptide doesn’t need to be placed directly at an injury to work.
This sets BPC-157 apart from treatments that only act locally, like a cortisone shot that reduces inflammation in one specific joint. When BPC-157 is given orally or injected into the abdomen, it still reaches distant tissues and triggers repair processes. The peptide has been shown to promote stomach lining repair, accelerate wound closure, and even influence brain chemistry when given peripherally, meaning far from the brain itself.
It Survives Digestion Unusually Well
Most peptides (small protein fragments) break down within minutes in stomach acid. BPC-157 is a notable exception. It remains stable in human gastric juice for more than 24 hours. For comparison, epidermal growth factor and transforming growth factor alpha, two well-known healing peptides, degrade within minutes under the same conditions.
This stability translates into real absorption. Pharmacokinetic data shows oral bioavailability of 110 to 120%, meaning the peptide is essentially completely absorbed from the gastrointestinal tract. That figure falls within the standard confidence range (80 to 125%) used to confirm that an oral dose delivers the same amount of active compound as an intravenous dose. BPC-157 is always applied without a carrier substance, whether given orally, by injection, or topically.
How Quickly It Moves Through the Body
BPC-157 absorbs rapidly but also breaks down fast. Its elimination half-life is under 30 minutes, meaning half of the active peptide is gone from your system within that window. The body metabolizes it into six smaller peptide fragments. This short lifespan is one reason people who use it typically dose it once or twice daily rather than weekly, though it’s worth noting that no human pharmacokinetic studies exist to confirm optimal timing or dosing schedules.
It Crosses the Blood-Brain Barrier
One of the strongest pieces of evidence for BPC-157’s systemic nature is its ability to reach the brain after being given peripherally. When injected outside the central nervous system in rats, the peptide crossed the blood-brain barrier and altered serotonin production in specific brain structures. It also affected the dopamine system, preventing or reversing movement dysfunction caused by damage to dopamine-producing pathways.
In traumatic brain injury models, BPC-157 showed neuroprotective properties, protecting sensory neurons against toxic damage and restoring their function. It also significantly reduced harm and mortality from a neurotoxin that specifically targets dopamine neurons. These findings confirm that the peptide doesn’t stay at the injection site. It circulates, reaches the brain, and interacts with neurotransmitter systems.
Dosing From Animal Studies
No human clinical trials have established a standard dose. The closest estimates come from rat studies, where oral doses of 10 micrograms per kilogram of body weight showed benefit. Scaled to humans using standard conversion factors, that translates to roughly 1.6 micrograms per kilogram, or about 110 micrograms for a 150-pound person, 145 micrograms for a 200-pound person, and 180 micrograms for a 250-pound person. These are extrapolations, not clinically validated recommendations, and species differences in how the peptide is processed remain unstudied.
Regulatory Status in the U.S.
BPC-157 is not approved by the FDA for any medical use. It currently sits in a regulatory gray area. The FDA’s Pharmacy Compounding Advisory Committee has scheduled a meeting for July 2026 to discuss whether BPC-157 (both the free base and acetate forms) should be added to the list of substances that compounding pharmacies can legally prepare. The only use being formally evaluated at that meeting is for ulcerative colitis. Until the committee makes its recommendation, the compound’s availability through compounding pharmacies remains uncertain, and it is not legally marketed as a drug or dietary supplement for any condition.